Clinical trials: Negative Symptoms of Schizophrenia
Schizophrenia; Negative Type
Deep Brain Stimulation (DBS) for the Management of Treatment Refractory Negative Symptoms in Schizophrenia
Schizophrenia is a complex, challenging, and heterogeneous psychiatric condition, affecting up to 0.5% of the population and responsible for nearly 2% of all Canadian health-care expenditure.
- Trial name
- NCT01725334
- Testing
- Deep Brain Stimulation
- Where
- Canada
- Sponsor
- Centre for Addiction and Mental Health
Negative and Cognitive Symptoms in Schizophrenia
Minocycline for the Treatment of Early-Phase Schizophrenia
Current antipsychotics have only a limited effect on two core symptoms of schizophrenia, negative symptoms and cognitive deficits.
- Trial name
- NCT00733057
- Testing
- Minocycline
- Where
- Israel
- Volunteers
- 70 people
- Sponsor
- Shalvata Mental Health Center
Schizophrenia
Effect of Metacognitive Therapy on Negative Symptoms: a Case Series
Negative symptoms (e.g. diminished pleasure and motivation) are common in people with a diagnosis of schizophrenia. Little is known about the psychological mechanisms involved in negative symptom development and maintenance and…
- Trial name
- NCT03999112
- Testing
- Metacognitive Reflection and Insight Therapy (MERIT)
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- NHS Greater Glasgow and Clyde
Negative Symptoms of Schizophrenia
SPD489 as Adjunctive Treatment in Adults With Negative Symptoms of Schizophrenia
To assess the safety and efficacy of SPD489 low-dose and high-dose treatment groups to placebo when given as adjunctive therapy to antipsychotic medication in clinically stable adults with persistent predominant negative symptoms…
- Trial name
- NSS (NCT01234298)
- Testing
- SPD489 Low-Dose, SPD489 High-Dose
- Sponsor
- Shire
Schizophrenia
Treatment of Negative Symptoms and Schizophrenia
The aim of this study is to evaluate the therapeutic efficacy of a neuromodulation technique, tDCS (transcranial direct current stimulation) used as a complementary treatment on negative symptoms.
- Trial name
- STICCS (NCT02204787)
- Testing
- transcranial direct current stimulation
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Montpellier
Schizophrenia and Predominant Negative Symptoms
Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms
To explore the efficacy of SPD489, as adjunctive therapy to a stable dose of atypical antipsychotic medication, on negative symptoms in adult subjects with clinically stable schizophrenia and predominant negative symptoms, as…
- Trial name
- NCT00922272
- Testing
- SPD489 (lisdexamfetamine dimesylate)
- Where
- 27 sites in United States
- Volunteers
- 92 people
- Sponsor
- Shire
Schizophrenia
The Study of Minocycline for Negative and Cognitive Symptoms in Schizophrenia
The purpose of this study is to determine whether minocycline are effective in the treatment of negative and cognitive symptoms in schizophrenia.
- Trial name
- NCT01493622
- Testing
- minocycline
- Where
- China
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Central South University
Schizophrenia
Efficacy of Selegiline in Negative Symptoms of Schizophrenia
Antipsychotic drugs are effective in treating the positive symptoms of schizophrenia; however their efficacy in treating negative symptoms is limited.
- Trial name
- NCT00456976
- Testing
- Selegiline
- Where
- Iran
- Volunteers
- 70 people
- Sponsor
- Tabriz University
Schizophrenia
The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) for Negative Symptoms and Cognitive Impairment Associated With Schizophrenia
The primary objectives of this application are to determine if the selective ERβ agonist LY500307, when added to antipsychotic medications, improves negative and/or cognitive symptoms in patients with schizophrenia.
- Trial name
- Beta (NCT01874756)
- Testing
- LY500307 150mg, LY500307 75mg, LY500307 25mg
- Where
- 4 sites in United States
- Volunteers
- 95 people
- Sponsor
- Indiana University
Schizophrenia
Music Therapy Towards Schizophrenia, Negative Symptoms
The Aim of this National study is to examine whether music therapy can reduce negative symptoms and raise Quality of Life for patients suffering from Schizophrenia.
- Trial name
- NCT02942459
- Testing
- Music therapy, Music Listening
- Where
- Denmark
- Volunteers
- 120 people
- Sponsor
- Inge Nygaard Pedersen
Schizophrenia
Schizophrenia TreAtment With electRic Transcranial Stimulation
The aim of this study is to evaluate the therapeutic efficacy of tDCS (transcranial direct current stimulation) for treatment of negative symptoms in patients with schizophrenia.
- Trial name
- STARTS (NCT02535676)
- Testing
- Transcranial Direct Current Stimulation
- Where
- Brazil
- Volunteers
- 100 people
- Sponsor
- University of Sao Paulo
Schizophrenia
Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia
This is a study of a new medication for the treatment of cognitive impairments (thinking difficulties) and negative symptoms in people with schizophrenia. The new medication is rasagiline.
- Trial name
- NCT00492336
- Testing
- rasagiline (Pharmacodynamics)
- Where
- 5 sites in United States
- Volunteers
- 84 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia, Negative Symptoms in Schizophrenia
A Study on the Efficacy of Agomelatine Combined With Antipsychotics to Treat Negative Symptoms in Schizophrenia
This study is a prospective, multicenter, controlled, real world study. Patients will be randomly enrolled into the test group and the control group at a ratio of 1:1 during the screening period.
- Trial name
- NCT05646264
- Testing
- Agomelatine
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Shanghai Mental Health Center
Schizophrenia, Negative Symptoms
Effect of Add-on Citalopram to Risperidone on Negative Symptoms in Schizophrenia
Negative symptoms in schizophrenia present a challenge to the clinician owing to their poorer response to conventional treatment with antipsychotics.
- Trial name
- RIS-CIT-SCH (NCT00893256)
- Testing
- Risperidone, Citalopram
- Where
- India
- Volunteers
- 48 people
- Sponsor
- National Institute of Mental Health and Neuro Sciences, India
Schizophrenia
Adjuvant Treatment With a Glycine Uptake Inhibitor in Participants With Negative Symptoms of Schizophrenia (P05695) (MK-8435-001)
The purpose of this study is to determine whether MK-8435 (Org 25935) is more effective than placebo in improving negative symptoms in participants with schizophrenia who are concurrently treated with a stable dose of a second…
- Trial name
- GIANT (NCT00725075)
- Testing
- MK-8435 (Org 25935) 4-8 mg, MK-8435 (Org 25935) 12-16 mg
- Volunteers
- 215 people
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia, Negative Symptoms in Schizophrenia
Validation of the Lithuanian Version of the BNSS, CDSS, and the SCoRS
This study aims to validate the Lithuanian version of the Brief Negative Symptoms Scale, Calgary Depression Scale for Schizophrenia, and Schizophrenia Cognition Rating Scale in a Lithuanian sample.
- Conditions
- Schizophrenia, Negative Symptoms in Schizophrenia, Depressive Symptoms Due to Primary Psychotic Disorder (Diagnosis), Cognitive Deficit
- Trial name
- NCT06278532
- Testing
- Brief Negative Symptoms Scale, The Calgary Depression Scale for Schizophrenia, The Schizophrenia Cognition Rating Scale
- Where
- 2 sites in Lithuania
- Volunteers
- 200 people
- Sponsor
- Lithuanian University of Health Sciences
Schizophrenia
Pilot Study of Pregnenolone Augmentation Targeting Cognitive Symptoms in Persistently Symptomatic Patients With Schizophrenia
This is a pilot study of pregnenolone as an augmentation treatment for schizophrenia. The goal of this placebo-controlled study is to provide preliminary efficacy data for potential pregnenolone effects on cognitive symptoms and…
- Trial name
- NCT00560937
- Testing
- Pregnenolone
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Durham VA Medical Center
Schizophrenia
A Double-Blind Placebo Controlled Trial of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Negative Symptoms in Schizophrenia
There is pilot data to suggest the therapeutic value of rTMS applied to the left prefrontal cortex in the treatment of negative symptoms.
- Trial name
- rTMS (NCT00168311)
- Testing
- Transcranial Magnetic Stimulation
- Where
- Australia
- Volunteers
- 22 people
- Sponsor
- The Alfred
Schizophrenia
Double Blind, Placebo-controlled Study of Raloxifene for Negative Symptoms of Schizophrenia in Postmenopausal Women
Primary objective: To assess the efficacy of adding raloxifene as an adjunct to antipsychotic treatment to improve negative symptoms of schizophrenia in postmenopausal women.
- Trial name
- NCT01041092
- Testing
- raloxifene
- Where
- Spain
- Volunteers
- 34 people
- Sponsor
- Fundació Sant Joan de Déu
Schizophrenia
20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms (Study 165)
The purpose of this study is to evaluate the effect of AMG 747 on negative symptoms of schizophrenia in patients who are stable on current antipsychotic treatment.
- Trial name
- NCT01568229
- Testing
- AMG 747
- Where
- 44 sites in United States, Czechia and 4 more
- Volunteers
- 111 people
- Sponsor
- Amgen